{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T10:40:16Z","timestamp":1780483216580,"version":"3.54.1"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2010,2]]},"DOI":"10.1097\/id.0b013e3181cec8bc","type":"journal-article","created":{"date-parts":[[2010,1,28]],"date-time":"2010-01-28T06:06:35Z","timestamp":1264658795000},"page":"29-38","source":"Crossref","is-referenced-by-count":54,"title":["CTX Biochemical Marker of Bone Metabolism. Is It a Reliable Predictor of Bisphosphonate-Associated Osteonecrosis of the Jaws After Surgery? Part II: A Prospective Clinical Study"],"prefix":"10.1097","volume":"19","author":[{"given":"Cameron Y. S.","family":"Lee","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon B.","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210228","first-page":"111","article-title":"Osteonecrosis of the maxilla in a patient with a history of bisphosphonate therapy.","volume":"71","author":"Melo","year":"2005","journal-title":"J Can Dent Assoc"},{"key":"R2-6-20210228","doi-asserted-by":"crossref","first-page":"2374","DOI":"10.1016\/j.joms.2006.07.012","article-title":"Treating bisphosphonate osteonecrosis of the jaws: Is there a role for resection and vascularized reconstruction?","volume":"65","author":"Engroff","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"R3-6-20210228","doi-asserted-by":"crossref","first-page":"2646","DOI":"10.1016\/j.joms.2008.07.021","article-title":"Tetracycline-guided debridement and cone bam computed tomography for the treatment of bisphosphonate-related osteonecrosis of the jaw: A technical note.","volume":"66","author":"Fleisher","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"R4-6-20210228","doi-asserted-by":"crossref","first-page":"2397","DOI":"10.1016\/j.joms.2007.08.003","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk-factors, prediction of risk using serum CTX testing, prevention and treatment.","volume":"65","author":"Marx","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"R5-6-20210228","doi-asserted-by":"crossref","first-page":"2395","DOI":"10.1016\/j.joms.2007.10.002","article-title":"Serum CTX to prevent osteonecrosis\/orthodontic extraction of third molars: Paths toward minimizing surgical risk? [Editorial].","volume":"65","author":"Assael","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"R6-6-20210228","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1016\/j.joms.2007.12.048","article-title":"Serum CTX testing [Letter to the editor].","volume":"66","author":"Schwartz","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"R7-6-20210228","doi-asserted-by":"crossref","first-page":"1320","DOI":"10.1016\/j.joms.2008.01.054","article-title":"Oral bisphosphonate-induced osteonecrosis: Risk factors, prediction of risk using serum CTX testing, prevention, and treatment [Letter to the editor].","volume":"66","author":"Khosla","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"R8-6-20210228","first-page":"510","article-title":"Bisphosphonates and the dental patient: Part 2.","volume":"28","author":"Zak","year":"2007","journal-title":"Compend Contin Educ Dent"},{"key":"R9-6-20210228","first-page":"179","article-title":"Osteonecrosis of the jaw and biomarkers: What do we tell our patients? [Editorial].","volume":"23","author":"Koka","year":"2008","journal-title":"Int J Oral Maxillofac Implants"},{"key":"R10-6-20210228","first-page":"3930","article-title":"Collagen N-telopeptide excretion in men: The effects of age and intrasubject variability.","volume":"83","author":"Orwoll","year":"1998","journal-title":"J Clin Endoclinol Metab"},{"key":"R11-6-20210228","first-page":"3537","article-title":"Early changes in serum n- telopeptide and c-telopeptide cross-linked collagen type I predict long-term response to alendronate therapy in elderly women.","volume":"85","author":"Greenspan","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"R12-6-20210228","doi-asserted-by":"crossref","first-page":"694","DOI":"10.1093\/clinchem\/47.4.694","article-title":"Evaluation of a fully automated serum assay for c-terminal cross-linking telopeptide of type I collagen in osteoporosis.","volume":"47","author":"Garnero","year":"2001","journal-title":"Clin Chem"},{"key":"R13-6-20210228","doi-asserted-by":"crossref","first-page":"2290","DOI":"10.1093\/clinchem\/44.11.2290","article-title":"Clinical evaluation of the serum crosslaps one step ELISA, a new assay measuring the serum concentration of bone-derived degradation products of type I collagen C-telopeptides.","volume":"44","author":"Christgau","year":"1998","journal-title":"Clin Chem"},{"key":"R14-6-20210228","doi-asserted-by":"crossref","first-page":"2281","DOI":"10.1093\/clinchem\/44.11.2281","article-title":"Serum crosslaps one step ELISA. First application of monoclonal antibodies for measurement in serum of bone-related degradation products from C-terminal telopeptides of type I collagen.","volume":"44","author":"Rosenquist","year":"1998","journal-title":"Clin Chem"},{"key":"R15-6-20210228","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1007\/s002239900135","article-title":"Biochemical markers of bone turnover reflect femoral bone loss in elderly women.","volume":"59","author":"Dresner-Pollak","year":"1996","journal-title":"Calcif Tissue Int"},{"key":"R16-6-20210228","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.joms.2006.11.003","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws.","volume":"65","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"R17-6-20210228","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.joms.2009.01.009","article-title":"American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws\u20142009 update.","volume":"67","year":"2009","journal-title":"J Oral Maxillofac Surg"},{"key":"R18-6-20210228","doi-asserted-by":"crossref","first-page":"61","DOI":"10.14219\/jada.archive.2009.0019","article-title":"Oral bisphosphonate use and the prevalence of osteonecrosis of the jaw. An institutional inquiry.","volume":"140","author":"Sedghizadeh","year":"2009","journal-title":"J Am Dent Assoc"},{"key":"R19-6-20210228","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: Risk factors, recognition, prevention, and treatment.","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"R20-6-20210228","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1016\/j.joms.2006.10.061","article-title":"Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia.","volume":"65","author":"Mavrokokki","year":"2007","journal-title":"J Oral Maxillofac Surg"},{"key":"R21-6-20210228","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1007\/PL00005830","article-title":"Serum CTX: A new marker of bone resorption that shows treatment effect more often than other markers because of low coefficient of variability and large changes with bisphosphonate therapy.","volume":"66","author":"Rosen","year":"2000","journal-title":"Calcif Tissue Int"},{"key":"R22-6-20210228","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1016\/S8756-3282(00)00248-9","article-title":"Serum crosslaps for monitoring the response in individuals undergoing antiresorptive therapy.","volume":"26","author":"Christgau","year":"2000","journal-title":"Bone"},{"key":"R23-6-20210228","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/S8756-3282(98)00183-5","article-title":"Biochemical markers can predict the response in bone mass during alendronate treatment in early postmenopausal women.","volume":"24","author":"Ravn","year":"1999","journal-title":"Bone"},{"key":"R24-6-20210228","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1902\/jop.2007.060239","article-title":"Effect of long-term oral bisphosphonates on implant wound healing: Literature review and a case report.","volume":"78","author":"Wang","year":"2007","journal-title":"J Periodontol"},{"key":"R25-6-20210228","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.joms.2007.11.032","article-title":"Zoledronate, smoking, and obesity are strong risk factors for osteonecrosis of the jaw: A case-control study.","volume":"66","author":"Wessel","year":"2008","journal-title":"J Oral Maxillofac Surg"},{"key":"R26-6-20210228","doi-asserted-by":"crossref","first-page":"12","DOI":"10.14219\/jada.archive.2008.0002","article-title":"Closing in on the puzzle of ONJ [Editorial].","volume":"139","author":"Glick","year":"2008","journal-title":"J Am Dent Assoc"}],"container-title":["Implant Dentistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/ID.0b013e3181cec8bc","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,5,24]],"date-time":"2021-05-24T20:00:52Z","timestamp":1621886452000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/00008505-201002000-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,2]]},"references-count":26,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010]]}},"URL":"https:\/\/doi.org\/10.1097\/id.0b013e3181cec8bc","relation":{},"ISSN":["1056-6163"],"issn-type":[{"value":"1056-6163","type":"print"}],"subject":[],"published":{"date-parts":[[2010,2]]}}}